Free Trial

Immix Biopharma (IMMX) Competitors

Immix Biopharma logo
$2.72 +0.01 (+0.37%)
Closing price 04:00 PM Eastern
Extended Trading
$2.72 0.00 (0.00%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IMMX vs. AARD, BNTC, HRTX, AVIR, SGMT, MREO, NMRA, SCPH, MNPR, and EDIT

Should you be buying Immix Biopharma stock or one of its competitors? The main competitors of Immix Biopharma include Aardvark Therapeutics (AARD), Benitec Biopharma (BNTC), Heron Therapeutics (HRTX), Atea Pharmaceuticals (AVIR), Sagimet Biosciences (SGMT), Mereo BioPharma Group (MREO), Neumora Therapeutics (NMRA), scPharmaceuticals (SCPH), Monopar Therapeutics (MNPR), and Editas Medicine (EDIT). These companies are all part of the "pharmaceutical products" industry.

Immix Biopharma vs. Its Competitors

Immix Biopharma (NASDAQ:IMMX) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.

11.3% of Immix Biopharma shares are owned by institutional investors. 55.4% of Immix Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Immix Biopharma presently has a consensus price target of $7.00, indicating a potential upside of 157.35%. Aardvark Therapeutics has a consensus price target of $33.00, indicating a potential upside of 143.00%. Given Immix Biopharma's higher possible upside, analysts clearly believe Immix Biopharma is more favorable than Aardvark Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immix Biopharma
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Aardvark Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00

Aardvark Therapeutics' return on equity of 0.00% beat Immix Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Immix BiopharmaN/A -130.02% -86.33%
Aardvark Therapeutics N/A N/A N/A

In the previous week, Aardvark Therapeutics had 2 more articles in the media than Immix Biopharma. MarketBeat recorded 3 mentions for Aardvark Therapeutics and 1 mentions for Immix Biopharma. Immix Biopharma's average media sentiment score of 1.89 beat Aardvark Therapeutics' score of 0.96 indicating that Immix Biopharma is being referred to more favorably in the media.

Company Overall Sentiment
Immix Biopharma Very Positive
Aardvark Therapeutics Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Immix BiopharmaN/AN/A-$21.61M-$0.70-3.89
Aardvark TherapeuticsN/AN/A-$20.59MN/AN/A

Summary

Aardvark Therapeutics beats Immix Biopharma on 5 of the 9 factors compared between the two stocks.

Get Immix Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMMX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMMX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IMMX vs. The Competition

MetricImmix BiopharmaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$75.83M$3.01B$5.71B$9.54B
Dividend YieldN/A2.37%4.70%4.05%
P/E Ratio-3.8921.6328.2220.09
Price / SalesN/A332.55470.71102.59
Price / CashN/A41.5825.1828.40
Price / Book5.678.178.465.80
Net Income-$21.61M-$55.06M$3.25B$259.32M
7 Day Performance-9.03%4.48%2.72%1.42%
1 Month Performance25.35%18.40%10.78%11.84%
1 Year Performance21.43%3.05%34.15%17.00%

Immix Biopharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IMMX
Immix Biopharma
3.7984 of 5 stars
$2.72
+0.4%
$7.00
+157.4%
+21.0%$75.83MN/A-3.899
AARD
Aardvark Therapeutics
N/A$14.16
+3.0%
$33.00
+133.1%
N/A$307.27MN/A0.0018
BNTC
Benitec Biopharma
1.588 of 5 stars
$11.55
+2.5%
$26.00
+125.2%
+18.9%$303.21M$80K-7.6520
HRTX
Heron Therapeutics
3.7851 of 5 stars
$1.96
+2.9%
$5.00
+155.8%
-37.4%$298.26M$144.29M-32.58300Positive News
AVIR
Atea Pharmaceuticals
2.4408 of 5 stars
$3.45
+0.4%
$6.00
+74.2%
-0.5%$294.82MN/A-2.0970Positive News
SGMT
Sagimet Biosciences
2.6683 of 5 stars
$9.57
-0.4%
$26.60
+178.1%
+199.4%$293.97M$2M-5.458Gap Down
MREO
Mereo BioPharma Group
1.7681 of 5 stars
$1.83
+3.7%
$7.20
+294.5%
-57.6%$290.18M$10M-26.0740
NMRA
Neumora Therapeutics
2.4215 of 5 stars
$1.77
-6.6%
$7.14
+304.7%
-81.8%$287.91MN/A-1.11108
SCPH
scPharmaceuticals
4.3622 of 5 stars
$5.41
+0.5%
$14.00
+159.0%
+13.4%$285.54M$36.33M-2.8330Positive News
MNPR
Monopar Therapeutics
2.2425 of 5 stars
$46.73
+3.3%
$60.00
+28.4%
+1,149.2%$285.45MN/A-13.4110
EDIT
Editas Medicine
4.0772 of 5 stars
$3.43
+1.9%
$4.70
+37.2%
-44.2%$285.12M$32.31M-1.12230Analyst Upgrade

Related Companies and Tools


This page (NASDAQ:IMMX) was last updated on 7/28/2025 by MarketBeat.com Staff
From Our Partners